1. Home /
  2. Drug Approvals

Drug Approvals

Novartis Multiple Sclerosis Drug With Price Tag of $88,000 Gets FDA Nod

Novartis Multiple Sclerosis Drug With Price Tag of $88,000 Gets FDA Nod

Mayzent tablets to treat relapsing multiple sclerosis have been approved by the FDA. But the treatment comes with a hefty price tag.

What's Next for Biogen After It Terminates Trials for Alzheimer's Drug?

What's Next for Biogen After It Terminates Trials for Alzheimer's Drug?

Biogen has to now be considered a more likely buyout target given the breadth of its product portfolio.

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

Activists Aim to Eliminate Dual Role for Allergan CEO Saunders

David Tepper's Appaloosa LP renews calls for changes at the top.

I Like the Long Side of Bristol-Myers Squibb

I Like the Long Side of Bristol-Myers Squibb

Let's see what the charts and indicators look like.

Jim Cramer on Why Johnson & Johnson's Anti-Depressant Is Important

Jim Cramer on Why Johnson & Johnson's Anti-Depressant Is Important

Johnson & Johnson received FDA approval for a nasal spray designed to treat patients with depression.

Eli Lilly Stock Drops After Launching Cheaper Version of Top-Selling Insulin

Eli Lilly Stock Drops After Launching Cheaper Version of Top-Selling Insulin

Eli Lilly shares traded lower Monday after it said it plans to launch a cut-price version of its top selling insulin treatment Humalog as pressure to lower drug costs continues to ripple through the pharmaceutical industry.

Gilead Sciences Falls on Failed Cirrhosis Drug Trial of Selonsertib

Gilead Sciences Falls on Failed Cirrhosis Drug Trial of Selonsertib

Gilead Sciences says Selonsertib, a new drug for treating NASH, a type of liver disease, failed Phase 3 trials.

Merck Is Named No. 1 Pharma Pick at Bank of America

Merck Is Named No. 1 Pharma Pick at Bank of America

Strong sales of key cancer treatment drug Keytruda are expected to continue to drive revenues and earnings.

Chart of the Day, Part 1: Canopy Growth Could Be Key to Constellation Long Term

Chart of the Day, Part 1: Canopy Growth Could Be Key to Constellation Long Term

Analysts have noted that the weed leader's momentum is set to burn higher moving forward.

Real Money Goes Behind the Scenes of the Budding Cannabis Industry

Real Money Goes Behind the Scenes of the Budding Cannabis Industry

In the interest of due diligence, we went and took a close look at the ground floor of the newest investment craze.